Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9230MR)

This product GTTS-WQ9230MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9230MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15839MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ5821MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ9313MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ14234MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ4505MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ8415MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ10230MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ6063MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW